1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 05/20 11:29:38 am
35 SEK   +3.09%
05/17TRANSCRIPT : Biovica International AB - Analyst/Investor Day
CI
05/09Biovica's DiviTum«TKa at ASCO
AQ
04/28Biovica completes 510(k) submission for DiviTum«TKa to the FDA
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica announces the start of the TK IMPACT trial at Washington University of St Louis

11/24/2021 | 02:00am EDT

Biovica announced initiation of the TK IMPACT study, an investigator initiated prospective clinical trial at Washington University of St Louis to evaluate the clinical utility of the company's blood-based biomarker assay DiviTum?TKa on monitoring practices in the care of metastatic breast cancer patients. The study hypothesis is that incorporation of data from DiviTum?TKa measurements into the treatment monitoring of patients receiving standard first line treatment with CDK 4/6 inhibitors plus endocrine therapies, will be associated with the physicians' decision to change usage and/or timing of other routine monitoring tests such as CT scans and nuclear medicine exams. The study will examine care over time of 55 patients that will be tested regularly with DiviTum?TKa.


ę S&P Capital IQ 2021
All news about BIOVICA INTERNATIONAL AB (PUBL)
05/17TRANSCRIPT : Biovica International AB - Analyst/Investor Day
CI
05/09Biovica's DiviTum«TKa at ASCO
AQ
04/28Biovica completes 510(k) submission for DiviTum«TKa to the FDA
AQ
04/28Biovica completes 510(k) submission for DiviTum«TKa to the FDA
CI
04/28Biovica Capital Markets Day invitation May 17, 2022
AQ
03/22Positive DiviTum«TKa results published in npj Breast Cancer
AQ
03/15TRANSCRIPT : Biovica International AB, Q3 2022 Earnings Call, Mar 15, 2022
CI
03/15Biovica International AB Provides Earnings Guidance for the Full Year 2022
CI
03/15Biovica International AB Reports Earnings Results for the Third Quarter and Nine Months..
CI
03/14Biovica establishes US CLIA lab to further strengthen DiviTum«TKa launch
AQ
More news
Financials
Sales 2022 1,00 M 0,10 M 0,10 M
Net income 2022 -37,1 M -3,73 M -3,73 M
Net cash 2022 120 M 12,0 M 12,0 M
P/E ratio 2022 -17,6x
Yield 2022 -
Capitalization 997 M 100 M 100 M
EV / Sales 2022 877x
EV / Sales 2023 5,10x
Nbr of Employees 26
Free-Float 42,9%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 33,95
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving Chief Financial Officer, Executive VP & IR Contact
Lars Erik Holmqvist Chairman
Otti Bengtsson Gref Vice President-Research & Development
Tomas Andersson Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
BIOVICA INTERNATIONAL AB (PUBL)-18.00%98
EXACT SCIENCES CORPORATION-30.62%9 501
BGI GENOMICS CO., LTD.-24.52%3 962
GUARDANT HEALTH, INC.-65.26%3 542
IOVANCE BIOTHERAPEUTICS, INC.-21.69%2 350
SEEGENE, INC.-30.57%1 626